|
|
 |
| Vaccine Policy and
Licensure |
|
| Position Papers from the World Health Organization |
|
| Global
Advisory Committee on Vaccine Safety (GACVS) List |
back
to top |
|
|
|
GACVS: 16th Meeting, December 12-13,
2007
Issues discussed included: Guillain-Barré Syndrome
and vaccination; and hepatitis B vaccination and rheumatoid
arthritis. |
|
| HTML | PDF |
GACVS: 16th Meeting, June 12-13, 2007
Issues discussed included: statements on Menactra update, monitoring vaccine
safety, safety of BCG, and safety of rotavirus vaccine. |
|
| HTML | PDF |
GACVS: 15th Meeting, November 29-30,
2006
Issues
discussed included: Monitoring vaccine safety; report of the
WHO Expert Committee on Biological Standardization; safety
of vaccine formulations; vaccinating adolescents and young
adults: problems with coincidental pathologies and safety
assessments; safety of mumps vaccine strains; safety of BCG
vaccine in HIV-infected children; update on Menactra and Guillain-Barré syndrome;
pandemic influenza vaccines; safety of Japanese encephalitis
vaccination in India; safety of pneumococcal conjugate vaccine. |
|
| HTML | PDF |
GACVS: 14th Meeting, June 6-7, 2006
Issues discussed included: Vaccine safety monitoring and the WHO Programme
for International Drug Monitoring; post-marketing surveillance of rotavirus
vaccines; safety of squalene; Immunogenic overload; safety of pandemic
influenza vaccines; safety issues of varicella vaccines; modus operandi
of the Committee and additional information. |
|
| HTML | PDF |
GACVS: 13th Meeting, December 1-2,
2005
Issues discussed included: Statements on pandemic influenza vaccine, adjuvants,
rotavirus vaccine, subacute sclerosing panencephalitis and measles vaccine,
chronic fatigue syndrome and hepatitis B vaccine, conjugate meningococcal
vaccine and Guillain-Barré Syndrome, and an update on the Vaccine
Safety Net project. |
|
| HTML | PDF |
GACVS: 12th Meeting, June 9-10, 2005
Issues discussed included: Statements on mouse brain-derived Japanese encephalitis
vaccine, safety of SA 14-14-2 Japanese encephalitis vaccine, isoniazid
resistance of bacilli Calmette-Guerin strains, international drug monitoring,
thimerosal, safety of hexavalent vaccines, subacute sclerosing panencephalitis
and measles vaccination, and national regulatory authorities planning
workshops. |
|
| HTML | PDF |
GACVS: 11th Meeting, December 2-3,
2004
Issues discussed included: Statements on the safety of adjuvants, thimerosal,
residual cellular DNA in vaccines, transmissible spongiform encephalopathies,
potential risk of vaccines produced in yeast, safety of hexavalent vaccines,
and yellow fever vaccine. |
|
| HTML | PDF |
GACVS: 10th Meeting, June 10-11, 2004
Issues discussed included: Statements on the safety of adjuvants, dengue
vaccine safety, and effect of DTP vaccination on child survival. |
|
| HTML | PDF |
GACVS: 9th Meeting, December 3-4, 2003
Issues discussed included: Statements on intranasal influenza virus vaccine,
influenza vaccines and neurological complications, influenza vaccination
of women during pregnancy, safety issues in the poliomyelitis eradication
campaign, and more. |
|
| HTML | PDF |
GACVS: 8th Meeting, June 11-12, 2003
Issues discussed included: Adverse events following mumps vaccination;
safety of smallpox vaccines; safety of BCG vaccination in immunocompromised
individuals; thimerosal. |
|
| HTML | PDF |
GACVS: 7th Meeting, December 16-17,
2002
Issues discussed included: MMR and autism; oculorespiratory syndrome; hepatitis
B vaccination and leukaemia. |
|
| HTML | PDF |
GACVS: 6th Meeting, June 20-21, 2002
Issues discussed included: Safety of thimerosal-containing vaccines; Hepatitis
B vaccine and leukaemia; hepatitis B vaccine and multiple sclerosis;
aluminium-containing vaccines and macrophagic myofasciitis; Bell palsy
following intranasal vaccination; potential adverse impact of routine
vaccination on child survival. |
|
| HTML | PDF |
GACVS:5th Meeting, March 23, 2001
Issues discussed included: Causality assessment of adverse events following
immunization. |
|
| HTML | PDF |
GACVS: 1st Meeting, September 14-15,
1999
Issues discussed included: About GAVCS; macrophagic myofasciitis and aluminum-containing
vaccines. |
|
| HTML | PDF |
This page was reviewed on January 29, 2008
|
|
IAC Home